• Teva Pharmaceutical Industries Ltd., of Jerusalem, said the FDA granted orphan drug exclusivity for Treanda (bendamustine) through October 2015 for indolent B-cell non-Hodgkin’s lymphoma that has progressed during or within six months of treatment with Rituxan (rituximab, Biogen Idec Inc. and Roche AG) or a rituximab-containing regimen.